Trump’s Efforts to Lower Prices Meet Resistance in Red States

When President Donald Trump took office last November, he promised to address the high prices that Americans have faced—prices that surged during President Joe Biden’s term due to 40-year-high inflation. So, the question arises: why are some red states resisting Trump’s attempts to lower prices, passing laws that seem to only increase health care costs?

To an extent, Trump is following through on his campaign commitments. He started by tackling fuel prices, which hit a peak of over $5 per gallon in June 2022. Now, the national average stands at around $3.14. Additionally, his administration also managed to reduce the soaring costs of eggs, which spiked due to the Biden administration’s strategies against avian flu. By May, egg prices had dropped by 11% compared to the previous month. Meanwhile, inflation has decreased to 2.35%, a significant drop from the 8.3% observed during Biden’s second year.

Trump has also focused on reducing drug prices, which have stubbornly remained high despite bipartisan efforts for reform. He issued several executive orders, including one on April 15 titled “Lowering Drug Prices by Once Again Putting Americans First,” which aims to be particularly impactful.

This order includes plans to reduce the prices that Medicare pays for drugs, ultimately benefiting taxpayers and seniors whose copayments depend on overall purchase costs. Trump’s administration had previously attempted to align Medicare reimbursements with the discounted rates hospitals receive under the 340B program, though these efforts faced legal roadblocks. His new order aims to lay a solid foundation for implementing these changes through a survey.

Medicare holds a significant share of the U.S. retail drug market, accounting for about 30%, while hospitals participating in the 340B program benefit from discounts totaling $66 billion. Unfortunately, these hospitals are not obligated to pass on the savings, and often don’t, instead charging full price and keeping the surplus. Successfully executing Trump’s plan could save Medicare up to $16 billion each year and lead to lower copayments for seniors.

However, several red states seem to be moving against these efforts, either supporting or enacting legislation that expands the 340B program. This year, Republican-led legislatures in South Dakota, Tennessee, and Oklahoma have passed pro-340B bills, pushed by hospital associations eager to maintain the program’s opaque nature, allowing them to profit without ensuring transparency in defining their patient base. It raises a valid question: how does a person filling a prescription in Hawaii qualify as a regular patient at an Ohio hospital?

340B hospitals don’t reveal their earnings from the program or how they allocate those funds, yet they claim without substantiation that regulating the program could lead to financial ruin. The bills in these states threaten civil penalties for any drugmaker seeking data from hospitals regarding their discounted products. It’s puzzling—why would lawmakers who identify as Republicans support anti-transparency measures?

Additionally, these actions contradict Trump’s initiative for transparency and could exacerbate the inflationary impacts of the 340B program. Research indicates that the program often elevates health care costs since participating hospitals are incentivized to maximize profits by prescribing more medications, particularly the pricier ones. The average cost per prescription at a 340B hospital is about 150% higher than at a non-340B facility. Reports from 2023 suggest that 340B is responsible for an additional $1 billion in health care costs for state and local governments.

In states like Tennessee, legislators have notably ignored fiscal notes that outline the financial ramifications of these bills. By doing so, they’ve chosen to benefit large nonprofit hospitals, negatively affecting state budgets and the everyday citizens facing increased health care expenses.

Large hospitals have been criticized for spending 340B funds lavishly on unnecessary items like art and extravagant architecture, as well as on initiatives that do not directly enhance patient care. It’s somewhat alarming.

Ultimately, lawmakers in these red states might need to explain to their constituents why they’re straying from the president’s agenda, especially in states like Ohio, Florida, and Wisconsin, where similar measures are being considered. It’s crucial for Republicans to align with Trump’s efforts to enhance transparency and reduce health care costs.